Donald R. Stanski, M.D. received his medical degree from the University of Calgary in Alberta, Canada and anesthesiology training at the Massachusetts General Hospital, Boston, MA. He undertook research training in the Division of Clinical Pharmacology, University of California, San Francisco under the direction of the late Dr. Lewis B. Sheiner in pharmacokinetic/dynamic modeling. In 1979 Dr. Stanski joined the faculty at Stanford University, Department of Anesthesia. He developed an anesthesia-oriented clinical pharmacology research program at the Palo Alto VA Hospital that examined drug concentration-EEG effect relationships for CNS drugs, clinical measurement of anesthetic and analgesic depth and the application of innovative pharmacometrics methods to clinical drug development. He served as chair of the Department of Anesthesia at Stanford University from 1992 to 1997. While on leave from Stanford University, from 1998 to 2001 he served as Vice-President, Scientific and Medical Affairs at Pharsight Corp., Mountain View, CA. where he co-founded a consulting practice that provided drug, disease and market modeling for drug development programs in the pharmaceutical industry. From 2004 to 2006 he undertook public serve at the Food and Drug Administration, Washington, DC, contributing to the introduction of quantitative, model-based drug development concepts into regulatory review and clinical drug development as part of the Critical Path program. Following emeritus retirement from Stanford University in 2006, he joined Novartis Pharma AG leading a new Modeling and Simulation department. This integrated group (systems biology, pharmacology, statistics) of quantitative scientists model relevant drug development processes to improve drug discovery and development decision-making. Modeling efforts in this department include biological and genetic pathways, inference analysis, tissue/organ responses, dose-response for efficacy and safety, biomarker identification, population pharmacokinetics, clinical trial simulation, market modeling and portfolio analysis.